Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 7 hours ago
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
about 7 hours ago
Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline...
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
about 7 hours ago
This year’s meeting of the American Society of Clinical Oncology is abuzz...
ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout
about 7 hours ago
Kelonia Therapeutics has shared the largest slice of data yet for an...
In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
about 23 hours ago
In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies...
ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’
1 day ago
The German biotech shared updated data from a phase 1 study of...
Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
2 days ago
Nine years after wowing the audience at the American Society of Clinical...
Entry Japan with Clarity, Execute with Confidence
2 days ago
For biopharmaceutical companies, Japan is one of the world’s most important markets...
AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval
2 days ago
AstraZeneca has shared data it believes can rescue anselamimab from a phase...
Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed
2 days ago
Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2...
Boston, China and the future of biotech
2 days ago
Senior Writer Darren Incorvaia talks with industry leaders and experts from Flagship...
Chutes & Ladders—Allogene swaps in CMO as new chief exec
2 days ago
After more than eight years at the helm of off-the-shelf CAR-T company...
ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study
2 days ago
Bristol Myers Squibb may have gone big in its pursuit of cereblon...